By Dr. Adam Brockman, DC, ND | Member, NuvoCell Biologics Medical Advisory Board
Published:
The regenerative biologic category has grown quickly, and with that growth has come a wide range of products making similarly broad claims. For chiropractors and integrative providers looking to implement regenerative medicine in their practice, knowing what to look for is more useful than any marketing claim. This guide walks through what to evaluate before you add any regenerative product for chiropractors or integrative practices to your offerings.
Key Takeaways
- Cell source matters. Ask for documentation of tissue origin, source-cell characteristics, and manufacturing controls.
- Secretome cargo should be documented through characterization and proteomics, not just implied by terms like “exosomes” or “stem cell-derived.”
- Ask every manufacturer about stability testing, storage specs, and batch-to-batch reproducibility.
- Ask the manufacturer to explain the product’s regulatory classification, intended use, and the evidence supporting its claims.
- Patient conversation language should be compliant, accurate, and something a provider can stand behind.
- Provider support infrastructure is just as important as the product itself for successful integration.
What Is the Secretome?
The secretome is the collection of substances that cells release into their surrounding environment. In mesenchymal stem cells (MSCs), it includes soluble proteins, such as growth factors and cytokines, along with extracellular vesicles (EVs). Exosomes are one type of EV. Both EVs and exosomes are components of the secretome.
Secretome composition can vary depending on the cell source and production conditions. This makes documented sourcing and characterization important when evaluating a secretome-based product.
Why Is Sourcing the Starting Point for Any Evaluation?
In the regenerative biologic space, sourcing is where product quality either starts or falls apart. Two products that both say “MSC-derived” or “exosome-based” can differ substantially in the consistency, characterization, and documented properties of their source material.
The key questions to ask any manufacturer about sourcing:
- What is the specific cell type used, and from what tissue is it derived?
- Is the donor tissue screened and tested before use?
- How are processing standards maintained for consistency across production batches?
- What regulatory standards are production batches manufactured to?
Wharton’s Jelly Mesenchymal Stem Cells (WJ-MSCs) have become one of the more frequently cited MSC sources in current research, in part because umbilical cord tissue is collected at birth without invasive procedures, and the cells themselves are perinatal in origin. Research on EV-based products has consistently highlighted that source cell type, donor characteristics, and culture conditions all affect the bioactive profile of the final product.
What Does Characterization Documentation Actually Mean?
There is an important difference between a product that contains extracellular vesicles and one whose bioactive cargo is actually characterized and documented. Most marketing does not make that distinction.
Extracellular vesicles carry biological cargo, including proteins, growth factors, and regulatory RNA, that reflects the biology of the cell that produced them. But not all EV-containing products document what that cargo actually is. ISEV’s MISEV2023 guidelines recommend complementary methods to characterize extracellular vesicle preparations, rather than relying on particle counts alone.
When evaluating a product, ask:
- Is the protein profile documented? Can the manufacturer provide a list of identified bioactive molecules?
- Is there evidence of cargo consistency across batches?
- How was the EV population characterized, and what evidence supports identifying it specifically as exosomes?
When a patient asks what is in something you are recommending, “extracellular vesicles derived from Wharton’s Jelly Mesenchymal Stem Cells” with documented bioactive content is a meaningfully different answer than a product that simply says “contains exosomes.”
How Should You Evaluate Formulation Stability?
Bioactive materials are sensitive to temperature, processing, environment and time. A product is only as good as its stability under real-world conditions. That means storage in a clinic, transit to a patient’s home, and daily use over weeks.
Stability considerations to ask about:
- Temperature stability: What are the storage requirements? What happens if the product is exposed to temperature variation during transit?
- Shelf life: What is the documented shelf life of the product, and how was it determined?
- Formulation format: Is the product formulated in a way that protects bioactive content, for example, through a defined carrier or delivery system?
- Batch consistency: What manufacturing standards are used, and can the manufacturer provide documentation regarding quality-control procedures and consistency across production batches?
These are practical questions. If the bioactive content degrades before it reaches the patient, the product does not do what the manufacturer says it does.
What Regulatory Positioning Should You Look For?
Wellness terminology and an FDA disclaimer do not, by themselves, establish compliance. When evaluating any product in this space, ask the manufacturer to explain the product’s regulatory classification, intended use, and the evidence supporting its claims.
A provider-facing product should be clearly and consistently positioned as a wellness product, not as a treatment for any specific condition. What that looks like in practice:
- Marketing language uses wellness terminology, not disease treatment claims
- The product includes an FDA disclaimer: “These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.”
- The manufacturer can explain the product’s regulatory classification and intended use
- Patient-facing materials stay within the same language boundaries as provider-facing materials
A product that overstates its evidence base or makes unapproved therapeutic claims creates compliance exposure for providers who recommend it. Wellness terminology and an FDA disclaimer alone do not establish compliance. Evaluate what the manufacturer claims, how they support those claims, and whether the regulatory classification matches the intended use.
A Practical Evaluation Checklist for Providers
The table below summarizes the core evaluation criteria in a format that can be used when reviewing any regenerative biologic product for practice adoption.
| Evaluation Criterion | What to Look For |
| Cell source | Defined tissue and cell source, documented donor screening, and characterization relevant to the finished product. |
| Sourcing transparency | Manufacturer can specify tissue origin, donor screening protocol, and process regulatory compliance. |
| Bioactive cargo documentation | Protein profile or secretome documented in product literature, not just “contains exosomes” |
| Formulation stability | Evidence of stability testing across temperature and time; storage and shelf-life specifications provided |
| Manufacturing consistency | What manufacturing standard is followed? Is documentation available regarding batch-to-batch reproducibility, quality control procedures, and manufacturing processes? |
| Regulatory positioning | Manufacturer can explain the product’s regulatory classification and intended use, and its claims are consistent with that positioning. |
| Provider support | Clinical education materials, patient-facing resources, and onboarding support available |
| Claims compliance | Marketing language stays within approved wellness claims; no disease treatment, cure, or prevention language |
| Finished-product evidence | Documentation of relevant safety and quality testing, plus evidence supporting the advertised benefits for the formulation and route of application |
| Practice integration | Clear usage guidance, staff training, patient education materials, ordering procedures, and an implementation plan that fits existing workflows |
This checklist reflects general product evaluation principles and is not a regulatory or legal assessment framework. Providers should conduct their own due diligence and consult applicable state and professional licensing requirements.
How Do You Talk to Patients About These Products Responsibly?
Once you have decided to carry a product, the patient conversation is where it gets real. A well-sourced, clearly formulated product with transparent documentation makes the patient conversation easier, because the claims the product supports are claims you can make accurately.
Some principles for responsible patient communication about regenerative biologic wellness products:
- Lead with what the product is, not what it does to a condition: “This is a non-invasive regenerative wellness solution developed by doctors for doctors, formulated with secretome derived from Wharton’s Jelly Mesenchymal Stem Cells.”
- For NuvoCell specifically, use company-approved terminology: describe it as supporting the body’s natural regeneration processes, supporting natural recovery, and promoting mobility and well-being, not as treating any specific diagnosis.
- Be honest about the evidence base: the research on MSC-derived EVs is active and promising, but most work is still in early stages
- Do not present NuvoCell as a replacement for medical care or as treating, curing, or preventing a disease or condition
Providers who build real credibility in this space are the ones who are honest and measured about what these products are. Overpromising is a short-term win and a long-term credibility problem.
How Does NuvoCell Approach These Criteria?
NuvoCell is a provider-dispensed, non-invasive regenerative wellness solution developed by doctors for doctors. Its formulations contain secretome derived from Wharton’s Jelly Mesenchymal Stem Cells.
NuvoCell contains bioactive ingredients that help support the body’s natural regeneration processes and is formulated for external use as part of a general wellness routine. NuvoCell is not positioned as a drug, is not intended to diagnose, treat, cure, or prevent any disease, and is dispensed exclusively through professional provider relationships rather than sold directly to consumers.
NuvoCell’s provider support includes clinical launch training, patient education materials, a provider marketing package, access to CE education through Torrentia, and a structured 60-day onboarding framework. For providers who want to evaluate the full product documentation, ingredient sourcing, and research base before making a decision:
Ready to evaluate NuvoCell for your practice? Book a discovery call to discuss the formulation, available product documentation, and provider support, and explore how NuvoCell could fit your existing workflow.
For more information on the product and provider model, visit the NuvoCell practitioner page.
Frequently Asked Questions
Many products in this space use the term “exosomes” as a general marketing descriptor without specifying what the EV population contains or how it was characterized. A product with documented bioactive cargo or “secretome” can specify the cell source, the types of bioactive molecules present, and evidence of batch consistency. That level of transparency is what allows a provider to make an accurate, defensible recommendation to a patient.
No, but you do need to know what questions to ask. A reputable manufacturer should be able to answer clearly: What is your cell source? How is your bioactive content documented? What are your stability specifications? What is your regulatory positioning? If a manufacturer cannot answer those questions clearly, walk away.
Review the product’s marketing materials, patient-facing copy, and any claims made by sales representatives. Any claim that implies the product treats, cures, or prevents a specific disease or condition is outside compliant wellness product territory. The product should include an FDA disclaimer. Ask the manufacturer to explain the product’s regulatory classification, intended use, and the evidence supporting its claims. Wellness terminology and an FDA disclaimer do not, by themselves, establish compliance.
At a minimum: clinical education materials you can review before recommending the product, patient-facing resources that use compliant language, and some form of provider onboarding. A company that cannot support the provider’s introduction of the product into their practice is asking the provider to do significant work that the manufacturer should be handling.
NuvoCell is a provider-dispensed, non-invasive regenerative wellness solution developed by doctors for doctors, formulated with secretome derived from Wharton’s Jelly Mesenchymal Stem Cells. It is supported by clinical launch training, patient education materials, a provider marketing package, access to CE education through Torrentia, and a structured 60-day onboarding framework. It is not sold direct to consumer and is not positioned as a drug or medical treatment.
